Systemic therapy options for unresectable and metastatic chordomas (Q33274146)

25 July 2017

1 reference

title

Systemic therapy options for unresectable and metastatic chordomas (English)

1 reference

25 July 2017

0 references

1 reference

1

0 references

Paolo Giovanni Casali

series ordinal

2

0 references

language of work or name

1 reference

1 August 2011

1 reference

25 July 2017

published in

Current Oncology Reports

1 reference

25 July 2017

volume

13

1 reference

25 July 2017

issue

4

1 reference

25 July 2017

page(s)

323-330

1 reference

Brachyury expression in extra-axial skeletal and soft tissue chordomas: a marker that distinguishes chordoma from mixed tumor/myoepithelioma/parachordoma in soft tissue

25 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS11912-011-0176-X

Familial chordoma, a tumor of notochordal remnants, is linked to chromosome 7q33

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-011-0176-X

Mapping of candidate region for chordoma development to 1p36.13 by LOH analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-011-0176-X

Tuberous sclerosis: A case report with aortic aneurysm and unusual rib changes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-011-0176-X

Cervical chordoma in a patient with tuberous sclerosis presenting with shoulder pain

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-011-0176-X

Sacrococcygeal chordomas in patients with tuberous sclerosis complex show somatic loss of TSC1 or TSC2

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-011-0176-X

A molecular map of mesenchymal tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-011-0176-X

Brachyury, a crucial regulator of notochordal development, is a novel biomarker for chordomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-011-0176-X

Role of the transcription factor T (brachyury) in the pathogenesis of sporadic chordoma: a genetic and functional-based study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-011-0176-X

Chordoma of the mobile spine and sacrum: a retrospective analysis of a series of patients surgically treated at two referral centers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-011-0176-X

Chordoma.Thirty-five-year study at memorial hospital

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-011-0176-X

Sacral chordoma: 40-year experience at a major cancer center

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-011-0176-X

Patient outcome at long-term follow-up after aggressive microsurgical resection of cranial base chordomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-011-0176-X

Chordoma of the mobile spine: fifty years of experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-011-0176-X

Chordomas of the skull base: surgical management and outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-011-0176-X

Chordoma: long-term follow-up after radical photon irradiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-011-0176-X

Proton radiation therapy for chordomas and chondrosarcomas of the skull base

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-011-0176-X

A multidisciplinary team approach to skull base chordomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-011-0176-X

Combination of photon and proton radiation therapy for chordomas and chondrosarcomas of the skull base: the Centre de Protonthérapie D'Orsay experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-011-0176-X

High-dose radiotherapy in the management of chordoma and chondrosarcoma of the skull base and cervical spine: Part 1--Clinical outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-011-0176-X

Phase II study of high-dose photon/proton radiotherapy in the management of spine sarcomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-011-0176-X

Effectiveness and safety of spot scanning proton radiation therapy for chordomas and chondrosarcomas of the skull base: first long-term report

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-011-0176-X

Chordoma: A Clinicopathologic Study of Metastasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-011-0176-X

Chordoma of the mobile spine. A clinicopathologic analysis of 40 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-011-0176-X

Metastatic disease from spinal chordoma: a 10-year experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-011-0176-X

Prognostic factors in chordoma of the sacrum and mobile spine: a study of 39 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-011-0176-X

Clivus metastases: report of seven patients and literature review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-011-0176-X

Phase II study of 9-nitro-camptothecin in patients with advanced chordoma or soft tissue sarcoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-011-0176-X

Chemotherapeutic treatment of malignant chordoma in children

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-011-0176-X

Recurrent and metastatic clivus chordoma: systemic palliative therapy retards disease progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-011-0176-X

Expression of MDR1, HIF-1α and MRP1 in sacral chordoma and chordoma cell line CM-319

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-011-0176-X

Genome-wide analysis of sixteen chordomas by comparative genomic hybridization and cytogenetics of the first human chordoma cell line, U-CH1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-011-0176-X

Chromosome 7 abnormalities are common in chordomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-011-0176-X

Evaluation of 1p36 markers and clinical outcome in a skull base chordoma study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-011-0176-X

Methylthioadenosine phosphorylase and activated insulin-like growth factor-1 receptor/insulin receptor: potential therapeutic targets in chordoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-011-0176-X

Gain of chromosome 7 by chromogenic in situ hybridization (CISH) in chordomas is correlated to c-MET expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-011-0176-X

Molecular and biochemical analyses of platelet-derived growth factor receptor (PDGFR) B, PDGFRA, and KIT receptors in chordomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-011-0176-X

Analysis of receptor tyrosine kinases (RTKs) and downstream pathways in chordomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-011-0176-X

The role of epidermal growth factor receptor in chordoma pathogenesis: a potential therapeutic target

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-011-0176-X

Differential expression of epidermal growth factor receptor, c-Met, and HER2/neu in chordoma compared with 17 other malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-011-0176-X

Expression of hepatocyte growth factor and c-MET in skull base chordoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-011-0176-X

Expression of c-MET, low-molecular-weight cytokeratin, matrix metalloproteinases-1 and -2 in spinal chordoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-011-0176-X

Identifying mechanisms for therapeutic intervention in chordoma: c-Met oncoprotein

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-011-0176-X

Prostanoid receptor EP1 expression in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-011-0176-X

Ras, PI(3)K and mTOR signalling controls tumour cell growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-011-0176-X

Potential therapeutic targets for chordoma: PI3K/AKT/TSC1/TSC2/mTOR pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-011-0176-X

Aberrant hyperactivation of akt and Mammalian target of rapamycin complex 1 signaling in sporadic chordomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-011-0176-X

EGFR-dependent and independent activation of Akt/mTOR cascade in bone and soft tissue tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-011-0176-X

Sirolimus therapy in tuberous sclerosis or sporadic lymphangioleiomyomatosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-011-0176-X

Rapamycin (sirolimus) in tuberous sclerosis associated pediatric central nervous system tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-011-0176-X

The sonic hedgehog signaling network in development and neoplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-011-0176-X

Imatinib mesylate in chordoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-011-0176-X

Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteria.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-011-0176-X

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-011-0176-X

Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-011-0176-X

Sunitinib versus interferon alfa in metastatic renal-cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-011-0176-X

The activity of sunitinib against gastrointestinal stromal tumor seems to be distinct from its antiangiogenic effects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-011-0176-X

SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-011-0176-X

Multicenter phase II trial of sunitinib in the treatment of nongastrointestinal stromal tumor sarcomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-011-0176-X

Effectiveness of cetuximab/gefitinib in the therapy of a sacral chordoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-011-0176-X

Regression of cervical spinal cord compression in a patient with chordoma following treatment with cetuximab and gefitinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-011-0176-X

Response to erlotinib in a patient with treatment refractory chordoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-011-0176-X

Anti-tumor activity of GW572016: a dual tyrosine kinase inhibitor blocks EGF activation of EGFR/erbB2 and downstream Erk1/2 and AKT pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-011-0176-X

Discovery of a potent and orally active hedgehog pathway antagonist (IPI-926)

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-011-0176-X

Response to imatinib plus sirolimus in advanced chordoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-011-0176-X

Imatinib mesylate induces cisplatin hypersensitivity in Bcr-Abl+ cells by differential modulation of p53 transcriptional and proapoptotic activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-011-0176-X

STI571 sensitizes breast cancer cells to 5-fluorouracil, cisplatin and camptothecin in a cell type-specific manner

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-011-0176-X

STI-571 (Gleevec) potentiates the effect of cisplatin in inhibiting the proliferation of head and neck squamous cell carcinoma in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-011-0176-X

Long-term results: adjuvant radiotherapy in en bloc resection of sacrococcygeal chordoma is advisable.

21 January 2018

1 reference

12 December 2020

Chordoma of the cervical spine treated with vincristine sulfate

1 reference

12 December 2020

Response of lymphangioleiomyomatosis to a mammalian target of rapamycin inhibitor (temsirolimus) -based treatment.

1 reference

12 December 2020

The role of chemotherapy in pediatric clival chordomas

1 reference

12 December 2020

The sonic hedgehog pathway in chordoid tumours

1 reference

12 December 2020

Frequent loss of heterozygosity of the long arm of chromosome 7 is closely associated with progression of human gastric carcinomas

1 reference

12 December 2020

Radical radiation therapy of chordoma

1 reference

12 December 2020

Does the tuberous sclerosis complex include clivus chordoma? A case report

1 reference

12 December 2020

The effects of the novel, reversible epidermal growth factor receptor/ErbB-2 tyrosine kinase inhibitor, GW2016, on the growth of human normal and tumor-derived cell lines in vitro and in vivo.

1 reference

12 December 2020

Combination of PI3K/mTOR inhibition demonstrates efficacy in human chordoma.

1 reference

12 December 2020

Clivus chordoma in a child with tuberous sclerosis: CT and MR demonstration

1 reference

12 December 2020

The prognostic value of Ki-67, p53, epidermal growth factor receptor, 1p36, 9p21, 10q23, and 17p13 in skull base chordomas

1 reference

12 December 2020

Results of single-agent and combination chemotherapy for advanced soft tissue sarcomas. Implications for decision making in the clinic.

1 reference

12 December 2020

In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship.

1 reference

12 December 2020

Metastatic chordoma use of mechlorethamine (nitrogen mustard) in chordoma therapy

1 reference

12 December 2020

Combined antiproliferative activity of imatinib mesylate (STI-571) with radiation or cisplatin in vitro.

1 reference

12 December 2020

A tumor suppressor locus in familial and sporadic chordoma maps to 1p36.

1 reference

12 December 2020

10.1007/S11912-011-0176-X

Identifiers

DOI

1 reference

Dimensions Publication ID

25 July 2017

1002073225

0 references

1 reference